Health Care Reform and the Changing Dynamics Between Payers and Drug Makers
This article was originally published in RPM Report
Executive Summary
Why drug makers should pay close attention to the pressures bearing down on payers.
You may also be interested in...
When Interests Align: Medication Adherence
When you think about the impact of the Food & Drug Administration’s focus on real-world drug safety, the disruptive implications of the Affordable Care Act, and the relentless pressure to find savings in health care, it is easy to see the dangers posed to biopharma companies. But those forces aren’t all negative. In fact, they are helping to mobilize government, consumer groups and payors to push hard on at least one decidedly pro-pharma agenda: improving adherence with prescription medicines.
Health Care Reform and the Biopharma Sector: A Complete Tactical Victory
The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?
Medicare Price Negotiation -- Waiting for the Other Shoe to Drop
At present, the federal government is prohibited from negotiating outpatient prescription drug prices with pharmaceutical companies on behalf of Medicare Part D. But, Senator Barack Obama (and perhaps John McCain, whose stance on this policy is unclear) favors a health system in which the government can bring its bargaining power to the table. What happens when the other shoe drops?